The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

We live in an era of genomic medicine. The past five years brought about many significant
achievements in the field of cancer genetics, driven by rapidly evolving technologies and …

Background Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of
undetermined significance (CCUS) are defined by somatic mutations in genes associated …

Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex
microenvironment, complicating efforts to understand how different cell types contribute to …

Abstract Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the
oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 …

Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to
ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by …

Abstract Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the
mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their …

Some cancers originate from a single mutation event in a single cell. Blood cancers known
as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is …

Tumours most often arise from progression of precursor clones within a single anatomical
niche. In the bone marrow, clonal progenitors can undergo malignant transformation to …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …